Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Myelodysplastic Syndromes 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma 4Leukemia 4Leukemia, Myeloid, Acute 3Hematologic Neoplasms 3Lymphoma, Non-Hodgkin 2Immunoproliferative Disorders 2Immune System Diseases 2Cytokine Release Syndrome 2Triple Negative Breast Neoplasms 1Primary Immunodeficiency Diseases 1Osteopetrosis 1Neurotoxicity Syndromes 1Neoplasm, Residual 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma, B-Cell 1Lymphohistiocytosis, Hemophagocytic 1Lymphatic Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Epstein-Barr Virus Infections 1Cytopenia 1Breast Neoplasms 1Anemia, Refractory, with Excess of Blasts 1Anemia, Aplastic 1

Interventions

Cyclophosphamide 5Mycophenolic Acid 4Sirolimus 3fludarabine phosphate 2Whole-Body Irradiation 2Tacrolimus 2Methotrexate 2Melphalan 2Cyclosporine 2Busulfan 2vedolizumab 1ruxolitinib 1ibrutinib 1fludarabine 1baricitinib 1axatilimab 1Vorinostat 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Etoposide 1Blood Specimen Collection 1Abatacept 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Graft vs Host Disease × AP 1903 reagent × Clear all
NCT01744223 2022-07-12

Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant

Bellicum Pharmaceuticals

Phase 1/2 Active not recruiting
36 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡